Isis Pharmaceuticals News

CARLSBAD, Calif., Nov. 23 /PRNewswire-FirstCall/ -- Dear Isis Supporters and Shareholders, I would like to start by thanking you for your continuing support of Isis.

Moreover, each company is scored relative to its market index and its industry group.

An experimental drug for patients genetically disposed to extreme high cholesterol being developed by Isis Pharmaceuticals Inc and Genzyme Corp significantly lowered cholesterol in a pivotal late-stage study, according to data presented on Tuesday.

Posted November 17, 2009, 2:14 p.m. Stock of Carlsbad-based biotech Isis Pharmaceuticals plunged 17.01% today to $11.12 on good/bad news.

An experimental drug from Isis Pharmaceuticals and Genzyme cut levels of "bad" LDL cholesterol by 25% in patients with a rare genetic disorder that causes extremely high and dangerous levels of cholesterol, according to data presented today at a medical meeting.

Isis Pharmaceuticals reported encouraging results yesterday with a cholesterol-lowering drug but also extended the timeline for getting it on the market.

Isis Pharmaceuticals Inc. Very heavy share volume is apparent at Isis, the drug-maker that, with Genzyme Corporation produces mipomersen, a drug that reduces bad cholesterol in patients genetically disposed to high levels.

The National Association of Regulatory Utility Commi... AUSTIN, Texas-- --Lone Star Overnight , a Texas-based regional overnight package delivery company, is introducing a competitive multiple-package shipment rating option.

This is a follow up to my post, " ISIS Pharmaceuticals breaches long term support ." As many of you may know, posts from this blog are often syndicated on SeekingAlpha.com. In the case of my previous post on ISIS, I caught significant flack from the Seeking Alpha community .

Altair Therapeutics, Inc., a privately-held, biopharmaceutical company developing novel therapeutics for respiratory diseases, today announced that it has secured $17 million in a subsequent financing round.

A complete list of all headlines and biomedical stock developments can be found on BioMedReports.Com On 11/05/09, Isis Pharmaceuticals, Inc.

Isis Pharmaceuticals Inc. filed Quarterly Report for the period ended 2009-09-30. Isis Pharmaceuticals Inc.

Drug stocks gained Thursday, but shares of Alnylam Pharmaceuticals fell a day after the company reported a widened third-quarter loss and said its search for research partners is taking longer than expected.

Xconomy.com -- Isis Pharmaceuticals likes to talk about how its gene-silencing technology known as antisense creates so many innovative ideas for new drugs that it cana t commercialize them all itself, so it spins a few off into what CEO Stanley Crooke calls a oesatellite companies.a One of the more interesting ideas orbiting around Isis in ...

Regulus Therapeutics Inc., founded by Alnylam Pharmaceuticals, Inc. , and Isis Pharmaceuticals, Inc.

OUR TOP TWO IDEAS in the biotech sector remain Amgen and Isis Pharmaceuticals ; recent weakness, strong earnings from Amgen, and positive clinical data from Isis strengthen our enthusiasm for these stocks.

Earlier this week, Isis Pharmaceuticals, Inc. reported positive top-line results on its type II diabetes candidate, ISIS-113715. Results from the phase II study showed consistent and statistically significant reductions in multiple short and intermediate measures of glucose control.

Isis Pharmaceuticals, Inc. today announced positive top-line results from a Phase 2 study evaluating the safety and efficacy of ISIS 113715 in patients with type 2 diabetes.

I highlighted Isis Pharmaceuticals a few weeks ago believing that a sell-off causing a price decline from $19 to $16/share was a prime opportunity to buy a potential high-growth business.

FOLLOWING RECENT profit-taking, we are adding Onyx Pharmaceuticals to our biotechnology trading list.